Unaffected Li-Fraumeni Syndrome Carrier Parent Demonstrates Allele-Specific mRNA Stabilization of Wild-Type TP53 Compared to Affected Offspring
Open Access
Abstract
Li-Fraumeni Syndrome (LFS) is an autosomal dominant disorder where an oncogenic TP53 germline mutation is inherited by offspring of a carrier parent. p53 is a key tumor suppressor regulating cell cycle arrest in response to DNA damage. Unexpectedly, some mutant TP53 carriers remain unaffected, while their children develop cancer early in life. To begin unravelling this paradox, the response of dermal fibroblasts (dFb) isolated from a child with LFS was compared to those from her unaffected father after UV exposure. Phospho-Chk1[S345], a key activator of cell cycle arrest, was increased by UV induction in the LFS patient compared to their unaffected parent dFb. This result, along with previous findings of reduced CDKN1A/p21 UV induction in affected dFb, suggest that cell cycle dysregulation may contribute to cancer onset in the affected LFS subject but not the unaffected parent. Mutant p53 protein and its promoter binding affinity were also higher in dFb from the LFS patient compared to their unaffected parent. These results were as predicted based on decreased mutant TP53 allele-specific mRNA expression previously found in unaffected dFb. Investigation of the potential mechanism regulating this TP53 allele-specific expression found that, while epigenetic promoter methylation was not detectable, TP53 wild-type mRNA was specifically stabilized in the unaffected dFb. Hence, the allele-specific stabilization of wild-type TP53 mRNA may allow an unaffected parent to counteract genotoxic stress by means more characteristic of homozygous wild-type TP53 individuals than their affected offspring, providing protection from the oncogenesis associated with LFS.Keywords
Funding Information
- Soccer for Hope Foundation
- Center For Inherited Blood Disorders
- CHOC Mad Hatter Guild
- Doug George Memorial Charity
This publication has 52 references indexed in Scilit:
- More targets, more pathways and more clues for mutant p53Oncogenesis, 2013
- Transcriptional and epigenetic regulation of the p53 tumor suppressor geneEpigenetics, 2011
- Examination of the expanding pathways for the regulation of p21 expression and activityCellular Signalling, 2010
- TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypesJournal of Medical Genetics, 2010
- The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich elementProceedings of the National Academy of Sciences, 2009
- Distinct mechanisms act in concert to mediate cell cycle arrestProceedings of the National Academy of Sciences, 2009
- The Absence of Ser389 Phosphorylation in p53 Affects the Basal Gene Expression Level of Many p53-Dependent Genes and Alters the Biphasic Response to UV Exposure in Mouse Embryonic FibroblastsMolecular and Cellular Biology, 2008
- Mutation and methylation analysis of TP53 in adrenal carcinogenesisEuropean Journal of Surgical Oncology, 2005
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- Aberrant p21WAF1-dependent growth arrest as the possible mechanism of abnormal resistance to ultraviolet light cytotoxicity in Li–Fraumeni syndrome fibroblast strains heterozygous for TP53 mutationsOncogene, 1998